img

Global Pulmonary Arterial Hypertension (PAH) Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pulmonary Arterial Hypertension (PAH) Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The global Pulmonary Arterial Hypertension (PAH) Drugs market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Pulmonary Arterial Hypertension (PAH) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The China market for Pulmonary Arterial Hypertension (PAH) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The Europe market for Pulmonary Arterial Hypertension (PAH) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034..
The global key manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs include Pfizer, Glaxosmithkline, Novartis, United Therapeutics, AstraZeneca, Merck, Bayer Healthcare, Actelion Pharmaceuticals and Daiichi Sankyo, etc. In 2024, the global top five players hold a share approximately % in sales volume, and in term of revenue of Pulmonary Arterial Hypertension (PAH) Drugs, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Pulmonary Arterial Hypertension (PAH) Drugs by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Pulmonary Arterial Hypertension (PAH) Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Pulmonary Arterial Hypertension (PAH) Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Pfizer
Glaxosmithkline
Novartis
United Therapeutics
AstraZeneca
Merck
Bayer Healthcare
Actelion Pharmaceuticals
Daiichi Sankyo
Northern Therapeutics
Aires Pharmaceuticals
Arena Pharmaceuticals
Berlin Cures
Eiger BioPharmaceuticals
Reata Pharmaceuticals
By Type
Inhalation
Injectables
Oral Administration
By Application
Hospitals
Clinics
Other
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Pulmonary Arterial Hypertension (PAH) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Pulmonary Arterial Hypertension (PAH) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pulmonary Arterial Hypertension (PAH) Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Pulmonary Arterial Hypertension (PAH) Drugs Definition
1.2 Market by Type
1.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Inhalation
1.2.3 Injectables
1.2.4 Oral Administration
1.3 Market Segment by Application
1.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales
2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region
2.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2018-2023)
2.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2024-2034)
2.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Region
2.6.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Region (2018-2023)
2.6.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Manufacturers
3.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Drugs Sales in 2024
3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers
3.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers (2018-2023)
3.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Drugs Revenue in 2024
3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Manufacturers
3.4 Global Key Players of Pulmonary Arterial Hypertension (PAH) Drugs, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type
4.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type
4.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Historical Revenue by Type (2018-2023)
4.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type
4.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2018-2023)
4.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application
5.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application
5.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Historical Revenue by Application (2018-2023)
5.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application
5.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2018-2023)
5.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Company
6.1.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (2018-2023)
6.1.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Company (2018-2023)
6.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
6.2.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2018-2034)
6.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
6.3.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2018-2034)
6.4 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
6.4.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2018-2034)
6.4.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Company
7.1.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Company (2018-2023)
7.1.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (2018-2023)
7.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
7.2.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2018-2034)
7.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
7.3.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2018-2034)
7.4 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
7.4.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2018-2034)
7.4.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales by Company
8.1.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Company (2018-2023)
8.1.2 China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (2018-2023)
8.2 China Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
8.2.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2018-2034)
8.3 China Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
8.3.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales by Company
9.1.1 APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Company (2018-2023)
9.1.2 APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (2018-2023)
9.2 APAC Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
9.2.1 APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2018-2034)
9.3 APAC Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
9.3.1 APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2018-2034)
9.4 APAC Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region
9.4.1 APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2018-2034)
9.4.3 APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.1.5 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
11.1.6 Pfizer Recent Developments
11.2 Glaxosmithkline
11.2.1 Glaxosmithkline Company Information
11.2.2 Glaxosmithkline Overview
11.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.2.5 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
11.2.6 Glaxosmithkline Recent Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Overview
11.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.3.5 Novartis Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
11.3.6 Novartis Recent Developments
11.4 United Therapeutics
11.4.1 United Therapeutics Company Information
11.4.2 United Therapeutics Overview
11.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.4.5 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
11.4.6 United Therapeutics Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca Overview
11.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.5.5 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
11.5.6 AstraZeneca Recent Developments
11.6 Merck
11.6.1 Merck Company Information
11.6.2 Merck Overview
11.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.6.5 Merck Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
11.6.6 Merck Recent Developments
11.7 Bayer Healthcare
11.7.1 Bayer Healthcare Company Information
11.7.2 Bayer Healthcare Overview
11.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.7.5 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
11.7.6 Bayer Healthcare Recent Developments
11.8 Actelion Pharmaceuticals
11.8.1 Actelion Pharmaceuticals Company Information
11.8.2 Actelion Pharmaceuticals Overview
11.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.8.5 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
11.8.6 Actelion Pharmaceuticals Recent Developments
11.9 Daiichi Sankyo
11.9.1 Daiichi Sankyo Company Information
11.9.2 Daiichi Sankyo Overview
11.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.9.5 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
11.9.6 Daiichi Sankyo Recent Developments
11.10 Northern Therapeutics
11.10.1 Northern Therapeutics Company Information
11.10.2 Northern Therapeutics Overview
11.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.10.5 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
11.10.6 Northern Therapeutics Recent Developments
11.11 Aires Pharmaceuticals
11.11.1 Aires Pharmaceuticals Company Information
11.11.2 Aires Pharmaceuticals Overview
11.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.11.5 Aires Pharmaceuticals Recent Developments
11.12 Arena Pharmaceuticals
11.12.1 Arena Pharmaceuticals Company Information
11.12.2 Arena Pharmaceuticals Overview
11.12.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.12.5 Arena Pharmaceuticals Recent Developments
11.13 Berlin Cures
11.13.1 Berlin Cures Company Information
11.13.2 Berlin Cures Overview
11.13.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.13.5 Berlin Cures Recent Developments
11.14 Eiger BioPharmaceuticals
11.14.1 Eiger BioPharmaceuticals Company Information
11.14.2 Eiger BioPharmaceuticals Overview
11.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.14.5 Eiger BioPharmaceuticals Recent Developments
11.15 Reata Pharmaceuticals
11.15.1 Reata Pharmaceuticals Company Information
11.15.2 Reata Pharmaceuticals Overview
11.15.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products and Services
11.15.5 Reata Pharmaceuticals Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Pulmonary Arterial Hypertension (PAH) Drugs Value Chain Analysis
12.2 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pulmonary Arterial Hypertension (PAH) Drugs Production Mode & Process
12.4 Pulmonary Arterial Hypertension (PAH) Drugs Sales and Marketing
12.4.1 Pulmonary Arterial Hypertension (PAH) Drugs Sales Channels
12.4.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors
12.5 Pulmonary Arterial Hypertension (PAH) Drugs Customers
13 Market Dynamics
13.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends
13.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers
13.3 Pulmonary Arterial Hypertension (PAH) Drugs Market Challenges
13.4 Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Inhalation
Table 3. Major Manufacturers of Injectables
Table 4. Major Manufacturers of Oral Administration
Table 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2018-2023)
Table 9. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2024-2034)
Table 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2018-2023) & (K Pcs)
Table 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2018-2023)
Table 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2024-2034) & (K Pcs)
Table 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2024-2034)
Table 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 17. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Share by Manufacturers (2018-2023)
Table 18. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 19. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers (2018-2023)
Table 20. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturers 2018-2023 (USD/Pcs)
Table 21. Global Key Players of Pulmonary Arterial Hypertension (PAH) Drugs, Industry Ranking, 2021 VS 2024
Table 22. Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Pulmonary Arterial Hypertension (PAH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension (PAH) Drugs as of 2024)
Table 24. Global Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Product Offered and Application
Table 26. Global Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Share by Type (2018-2023)
Table 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Share by Type (2024-2034)
Table 32. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 33. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2018-2023)
Table 35. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2024-2034)
Table 36. Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2018-2023) & (USD/Pcs)
Table 37. Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 38. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 39. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 40. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Share by Application (2018-2023)
Table 41. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Share by Application (2024-2034)
Table 42. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 43. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2018-2023)
Table 45. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2024-2034)
Table 46. Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2018-2023) & (USD/Pcs)
Table 47. Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 48. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 49. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Company (2018-2023) & (K Pcs)
Table 50. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 51. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 52. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 53. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 55. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 56. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 57. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 59. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 60. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Country (2018-2023) & (K Pcs)
Table 62. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Country (2024-2034) & (K Pcs)
Table 63. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Company (2018-2023) & (K Pcs)
Table 64. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 65. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 66. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 67. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 68. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 70. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 71. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 72. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 74. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 75. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Country (2018-2023) & (K Pcs)
Table 77. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Country (2024-2034) & (K Pcs)
Table 78. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Company (2018-2023) & (K Pcs)
Table 79. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 80. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 81. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 82. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 83. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 85. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 86. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 87. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Company (2018-2023) & (K Pcs)
Table 89. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 90. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 91. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 92. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 93. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 95. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 96. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 97. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 99. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 100. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Region (2018-2023) & (K Pcs)
Table 102. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Region (2024-2034) & (K Pcs)
Table 103. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Company (2018-2023) & (K Pcs)
Table 104. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 105. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 106. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 107. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 110. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 111. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 112. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Country (2018-2023) & (K Pcs)
Table 117. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity by Country (2024-2034) & (K Pcs)
Table 118. Pfizer Company Information
Table 119. Pfizer Description and Overview
Table 120. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 121. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 122. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
Table 123. Pfizer Recent Developments
Table 124. Glaxosmithkline Company Information
Table 125. Glaxosmithkline Description and Overview
Table 126. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 127. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 128. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
Table 129. Glaxosmithkline Recent Developments
Table 130. Novartis Company Information
Table 131. Novartis Description and Overview
Table 132. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 133. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 134. Novartis Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
Table 135. Novartis Recent Developments
Table 136. United Therapeutics Company Information
Table 137. United Therapeutics Description and Overview
Table 138. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 139. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 140. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
Table 141. United Therapeutics Recent Developments
Table 142. AstraZeneca Company Information
Table 143. AstraZeneca Description and Overview
Table 144. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 145. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 146. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
Table 147. AstraZeneca Recent Developments
Table 148. Merck Company Information
Table 149. Merck Description and Overview
Table 150. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 151. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 152. Merck Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
Table 153. Merck Recent Developments
Table 154. Bayer Healthcare Company Information
Table 155. Bayer Healthcare Description and Overview
Table 156. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 157. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 158. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
Table 159. Bayer Healthcare Recent Developments
Table 160. Actelion Pharmaceuticals Company Information
Table 161. Actelion Pharmaceuticals Description and Overview
Table 162. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 163. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 164. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
Table 165. Actelion Pharmaceuticals Recent Developments
Table 166. Daiichi Sankyo Company Information
Table 167. Daiichi Sankyo Description and Overview
Table 168. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 169. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 170. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
Table 171. Daiichi Sankyo Recent Developments
Table 172. Northern Therapeutics Company Information
Table 173. Northern Therapeutics Description and Overview
Table 174. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 175. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 176. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs SWOT Analysis
Table 177. Northern Therapeutics Recent Developments
Table 178. Aires Pharmaceuticals Company Information
Table 179. Aires Pharmaceuticals Description and Overview
Table 180. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 181. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 182. Aires Pharmaceuticals Recent Developments
Table 183. Arena Pharmaceuticals Company Information
Table 184. Arena Pharmaceuticals Description and Overview
Table 185. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 186. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 187. Arena Pharmaceuticals Recent Developments
Table 188. Berlin Cures Company Information
Table 189. Berlin Cures Description and Overview
Table 190. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 191. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 192. Berlin Cures Recent Developments
Table 193. Eiger BioPharmaceuticals Company Information
Table 194. Eiger BioPharmaceuticals Description and Overview
Table 195. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 196. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 197. Eiger BioPharmaceuticals Recent Developments
Table 198. Reata Pharmaceuticals Company Information
Table 199. Reata Pharmaceuticals Description and Overview
Table 200. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 201. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 202. Reata Pharmaceuticals Recent Developments
Table 203. Key Raw Materials Lists
Table 204. Raw Materials Key Suppliers Lists
Table 205. Pulmonary Arterial Hypertension (PAH) Drugs Distributors List
Table 206. Pulmonary Arterial Hypertension (PAH) Drugs Customers List
Table 207. Pulmonary Arterial Hypertension (PAH) Drugs Market Trends
Table 208. Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers
Table 209. Pulmonary Arterial Hypertension (PAH) Drugs Market Challenges
Table 210. Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints
Table 211. Research Programs/Design for This Report
Table 212. Key Data Information from Secondary Sources
Table 213. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Product Picture
Figure 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type in 2024 & 2034
Figure 4. Inhalation Product Picture
Figure 5. Injectables Product Picture
Figure 6. Oral Administration Product Picture
Figure 7. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 8. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application in 2024 & 2034
Figure 9. Hospitals
Figure 10. Clinics
Figure 11. Other
Figure 12. Pulmonary Arterial Hypertension (PAH) Drugs Report Years Considered
Figure 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue 2018-2034 (US$ Million)
Figure 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity 2018-2034 (K Pcs)
Figure 17. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Region (2018-2023)
Figure 18. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 19. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 20. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 22. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 24. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 25. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 26. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 28. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Top 10 and Top 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity in 2024
Figure 30. The Top 10 and Top 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Drugs Revenue in 2024
Figure 31. Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 32. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 33. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2018-2034)
Figure 34. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 35. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2018-2034)
Figure 36. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Company in 2024
Figure 37. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Company in 2024
Figure 38. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 39. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2018-2034)
Figure 40. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 41. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2018-2034)
Figure 42. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Country (2018-2034)
Figure 43. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Share by Country (2018-2034)
Figure 44. U.S. Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 45. Canada Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 46. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Company in 2024
Figure 47. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Company in 2024
Figure 48. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 49. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2018-2034)
Figure 50. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 51. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2018-2034)
Figure 52. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Country (2018-2034)
Figure 53. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Share by Country (2018-2034)
Figure 54. Germany Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 55. France Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 56. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 57. Italy Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 58. Russia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 59. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Company in 2024
Figure 60. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Company in 2024
Figure 61. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 62. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2018-2034)
Figure 63. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 64. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2018-2034)
Figure 65. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Company in 2024
Figure 66. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Company in 2024
Figure 67. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 68. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2018-2034)
Figure 69. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 70. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2018-2034)
Figure 71. APAC Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Region (2018-2034)
Figure 72. APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Share by Region (2018-2034)
Figure 73. Japan Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 74. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 75. China Taiwan Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 76. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 77. India Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2018-2034) & (US$ Million)
Figure 78. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Company in 2024
Figure 79. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Company in 2024
Figure 80. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Quantity Mark